Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURSUIT-IV: Golimumab IV Induction in Ulcerative Colitis
NCT00488774Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2007
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of golimumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Started Aug 2007; status: terminated.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00488774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00488774.